Medtronic plc: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-05-22
Other years: 2025 vs 2024 · 2023 vs 2022
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Medtronic expanded its risk disclosures by adding two forward-looking risks around product differentiation and market disruptions including workforce stoppages, while removing a 2023 risk regarding financial sector instability. The company substantially modified 10 risks, most notably enhancing disclosures around climate change impacts, product quality and recalls, and competitive positioning. Overall, the risk factor section shifted focus from macroeconomic financial concerns to operational and market-based threats, reflecting evolving business priorities between the two filing periods.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

2
New Risks
1
Removed
10
Modified
22
Unchanged
🟢 New in Current Filing Our success depends on our ability to differentiate our product and keep pace with emerging technologies. 🔒
🟢 New in Current Filing Market disruptions resulting in diminished liquidity, or healthcare professional and staff strikes or other work stoppages, could adversely affect our revenues, results of operation, or financial condition. 🔒
🔴 No Match in Current Filing Instability in the financial sector could adversely affect our revenues, results of operation, or financial condition. 🔒
🟡 Modified Climate change, or legal, regulatory or market measures to address climate change may materially adversely affect our financial condition and business operations. 🔒
🟡 Modified Quality problems have in the past and could in the future lead to recalls or safety alerts, product liability claims, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition, and cash flows. 🔒
🟡 Modified We operate in a highly competitive industry and we may be unable to compete effectively. 🔒
🟡 Modified We have debt obligations that create risk. 🔒
🟡 Modified Failure to integrate acquired businesses into our operations successfully, or challenges related to the Company's strategic initiatives, including divestitures and third-party funding arrangements, as well as liabilities or claims relating to such acquired businesses, divestitures, or arrangements could adversely affect our business. 🔒
🟡 Modified Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition, and cash flows. 🔒
🟡 Modified Public health crises have had, and may continue to have, an adverse effect on certain aspects of our business, results of operations, financial condition, and cash flows. The nature and extent of future impacts are highly uncertain and unpredictable. 🔒
🟡 Modified The outcome of Medtronic, Inc.'s U.S. tax litigation could have a material adverse impact on our financial condition. 🔒
🟡 Modified Changes in the prices of our goods and services, customer purchasing patterns and stocking dynamics, and/or inflationary costs may have a material adverse effect on our business, results of operations, financial condition, and cash flows. 🔒
🟡 Modified Consolidation in the healthcare industry and the growing prevalence of ambulatory surgery centers (ASCs) could have an adverse effect on our revenues and results of operations. 🔒
13 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →